Valneva SE (NASDAQ:VALN) Short Interest Up 49.8% in March

Valneva SE (NASDAQ:VALN - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 42,400 shares, a growth of 49.8% from the February 29th total of 28,300 shares. Based on an average daily trading volume, of 10,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 0.1% of the company's stock are sold short.

Valneva Stock Down 0.4 %

NASDAQ VALN traded down $0.04 during mid-day trading on Friday, reaching $7.92. The stock had a trading volume of 4,629 shares, compared to its average volume of 17,189. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37. Valneva has a 1 year low of $6.58 and a 1 year high of $17.05. The stock has a market cap of $550.12 million, a PE ratio of -5.01 and a beta of 2.23. The company has a fifty day moving average price of $7.71 and a 200 day moving average price of $10.09.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VALN. Guggenheim reduced their target price on shares of Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Friday, March 22nd. HC Wainwright reissued a "buy" rating and set a $26.00 price objective on shares of Valneva in a research report on Thursday, March 21st.

Hedge Funds Weigh In On Valneva

Several hedge funds and other institutional investors have recently modified their holdings of VALN. UBS Group AG purchased a new stake in shares of Valneva during the 2nd quarter valued at about $31,000. Jane Street Group LLC boosted its stake in Valneva by 85.9% in the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock worth $569,000 after purchasing an additional 7,664 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in Valneva during the 1st quarter worth approximately $858,000. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.